Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?
BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott's diversified healthcare business is one of the main reasons why it remains a reliable dividend stock.
Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Prosecutors have declined to charge businesses in a number of recent cases—despite believing that senior employees were involved in wrongdoing.
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
Abbott Laboratories (ABT) beat Q2 expectations, with growth acceleration in the second half of 2026
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.
The cyberattack follows Abbott’s recent $21 billion purchase of Exact Sciences. Abbott did not disclose what kind of information was accessed.
The Morning Bull - US Market Morning Update Friday, Jul, 17 2026 US stock futures are drifting slightly lower this morning, with key index contracts such as the E-mini S&P 500 and Nasdaq-100 off by around 0.1% to 0.4%, as investors weigh tighter financial conditions against mixed global growth signals. A planned 25% US tariff on some Brazilian imports raises questions about costs for companies tied to global trade and agriculture, while US crude stockpiles and the Strategic Petroleum Reserve...
A recent acquisition is already bearing fruit.
Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.
Abbott Laboratories has reported its second-quarter 2026 results, with sales rising to US$12.59 billion from US$11.14 billion a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations declined to US$0.53. Despite lower net income, Abbott delivered better-than-expected adjusted earnings, lifted its full-year 2026 adjusted EPS guidance, and highlighted strong growth in higher-margin Medical Devices and Cancer Diagnostics, signalling a continued shift in...
Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the...
ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara
Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r
The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures...
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
